Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsSharp Health Plan formulary coverage & PA update |…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentSharp-Health-PlanPolicy N/A

    List of Covered Prescription Drugs (4-Tier Large Group HMO/POS)

    Customize your policy alerts

    Sign up for all Sharp-Health-Plan policy alerts

    Know when Sharp-Health-Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the Sharp Health Plan prescription drug list (formulary) for employer-sponsored Large Group HMO and POS products that use a 4-tier formulary. It governs covered outpatient prescription drugs, plan-specific cost-sharing information, and formulary management for affected commercial employer groups.

    Policy Summary
    PayerSharp-Health-Plan
    PolicyList of Covered Prescription Drugs (4-Tier Large Group HMO/POS)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewMay 1, 2026
    Next Review DateMay 1, 2026
    Key ActionPrescribing provider must request prior authorization by phone, fax, or electronic form and submit required supporting clinical information when a drug is flagged PA.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4 Tierformulary design
    05/01/2026document update date
    Large Group HMO/POSapplicable product lines
    7-dayIR opioid supply threshold
    30-dayER opioid cumulative threshold
    $250oral anti-cancer copay cap

    Coverage Criteria and Formulary Governance

    Formulary scope and governance

    Coverage is organized by therapeutic class and includes governance on definitions, formulary changes, prior authorization, quantity limits, step therapy, specialty drugs, and appeals.

    Formulary governance: Applies to Sharp Health Plan employer-sponsored Large Group HMO and POS products using a 4‑tier formulary; providers must reference the electronic Formulary for current coverage and cost‑sharing information.

    Formulary maintained and updated periodically; see Definitions and Table of Contents for scope.

    General formulary coverage rules

    Covered when ALL of the following are met

    Formulary listing: Drug is FDA‑approved for the requested indication AND is listed on the Sharp Health Plan Formulary for the outpatient pharmacy benefit.

    Presence on the Formulary does not guarantee appropriate prescribing for a specific patient.

    Policy Summary
    PayerSharp-Health-Plan
    PolicyList of Covered Prescription Drugs (4-Tier Large Group HMO/POS)
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective DateN/A
    Last ReviewMay 1, 2026
    Next Review DateMay 1, 2026
    Key ActionPrescribing provider must request prior authorization by phone, fax, or electronic form and submit required supporting clinical information when a drug is flagged PA.
    SourceLink
    On This Page
    Coverage Criteria and Formulary GovernanceFormulary Listings and Code TablesProvider Steps, Prior Authorization and DocumentationInitial Therapy and Age-Based LimitsStep Therapy Criteria and Program RulesQuantity Limits and Measurement PeriodsDispensing Channels and Supply OptionsBackground and Definitions
    Benefit assignment: Drug is dispensed through the outpatient pharmacy benefit (retail, specialty or mail order). Drugs that are physician‑administered or self‑injectable may be covered under the Medical Benefit instead.

    Refer to Member Handbook for Medical Benefit cost‑sharing and coverage details.

    Authorization requirements

    Prior Authorization and Step Therapy conditions

    Prior Authorization (PA): If a drug is marked PA on the Formulary, the Prescribing Provider must obtain prior authorization before Sharp Health Plan will cover the drug.72 hours (non‑urgent) / 24 hours (urgent/Exigent)

    Providers submit PA by phone, fax, or electronic form; if Plan fails to respond within the timeframe a completed request is deemed granted.

    PA** (PA if Step Therapy not met): Drugs marked PA** require prior authorization based on specific clinical criteria when Step Therapy criteria have not been met.same timeframes as PA

    Providers may request PA to bypass Step Therapy when medically necessary and must submit supporting clinical documentation.

    Utilization Management Criteria

    Coverage decisions and exceptions for outpatient prescription drugs are governed as follows:

    Completed request requirement: Provider must submit a completed Prior Authorization or Step Therapy Exception request including all required supporting clinical information.Plan decision within 72 hours (non‑urgent) or 24 hours (urgent/Exigent)

    If incomplete, the plan will notify the provider what additional information is needed within the same timeframes.

    Quantity Limits (QL): If a drug is marked QL on the Formulary and the requested quantity exceeds the QL, the provider must document medical necessity on the PA request for consideration.Decision within 72/24 hours

    QLs are imposed for safety, overdose/abuse risk, or to reflect usual dosing; requests exceeding QL require justification.

    Step Therapy (ST): If a drug is marked ST, coverage depends on prior trial of specified preferred agent(s) unless a Step Therapy Exception is granted.Provider may request Step Therapy Exception; decision timeframes as above

    Members transitioning from another plan who are already taking the medication are generally exempt to preserve continuity of care.

    Formulary Exception: For a Nonformulary drug, the prescriber or member may request a Formulary Exception by submitting a PA/Formulary Exception request with supporting clinical information.Decision within 72/24 hours

    If approved, coverage (including refills) is provided for the duration indicated; nonformulary brand on approval is Tier 3, nonformulary generic is Tier 1.

    Formulary Exception Criteria

    Nonformulary drugs and formulary exceptions are handled as follows:

    Formulary exception request: Prescriber, member, or authorized representative may request a Formulary Exception for Nonformulary drugs by submitting a Prior Authorization/Formulary Exception request with supporting clinical documentation.Decision within 72 hours (non‑urgent) or 24 hours (urgent/Exigent)

    If approved, coverage (and refills) will be provided for the duration of the prescription; cost share will be applied per tier rules.

    Opioid ER step therapy (Group 2219-M)

    Covered when ONE of the following is met:

    Prior immediate‑release opioid exposure: Member has filled a cumulative 7‑day or greater supply of an immediate‑release (IR) opioid within the past 90 days.Cumulative ≥7 days within 90 days

    Satisfies step therapy for Step Therapy Group OPIOID ER 2219‑M.

    Prior extended‑release opioid exposure: Member has been receiving an extended‑release (ER) opioid for a cumulative 30 days or greater within the past 90 days.Cumulative ≥30 days within 90 days

    Satisfies step therapy for Step Therapy Group OPIOID ER 2219‑M.

    Opioid IR combo short-course coverage

    Special allowance for short-course IR opioids:

    Short‑course immediate‑release allowance: If the member does not have at least a cumulative 7‑day supply of any opioid (IR or ER) within the past 90 days, coverage will be provided for up to a 7‑day supply of immediate‑release opioids.Up to 7 days

    Applies to OPIOID IR COMBO PRODUCTS (Group 1358‑E).

    Coverage criteria (step therapy and PA/QL)

    Coverage conditions and limits for step therapy and stimulant/weight‑management agents

    Opioid ER coverage condition: Coverage for ER opioids provided when member meets opioid exposure thresholds (cumulative ≥7 days IR within past 90 days OR cumulative ≥30 days ER within past 90 days).See opioid step therapy thresholds

    From Step Therapy Group OPIOID ER 2219‑M.

    Opioid IR initiation allowance: If no prior opioid supply in past 90 days, coverage may be provided for up to a 7‑day supply of IR opioids.7‑day supply

    From Step Therapy Group OPIOID IR COMBO PRODUCTS 1358‑E.

    Stimulant PA and QL: Many amphetamine‑class and related stimulant products require Prior Authorization and are subject to Quantity Limits; age‑based PA commonly applies for members aged ≥19.PA required for age >=19 (where stated); QL examples: 360 tabs/75 days, 180 tabs/75 days, 90 caps/75 days

    Includes WEGOVY and other anti‑obesity agents where PA is indicated.

    Covered with conditions

    Coverage requirements and limits vary by product; many are covered with conditions

    Product‑specific management: Each product listing includes a Drug Tier and may include COVERAGE REQUIREMENTS AND LIMITS flags (PA, PA**, ST, QL, MO, SP); coverage is provided when those product‑level requirements are met.See product‑specific entries for PA/QL/ST/MO/SP

    Providers must follow the Formulary entry controls for each drug.

    Stimulant product coverage

    Methylphenidate products

    Adult PA requirement for methylphenidate: Prior Authorization is required for many methylphenidate ER/OROS and transdermal patch products for members age ≥19.age >= 19

    Quantity limits typically apply (e.g., 90 or 180 units per 75 days depending on product/strength).

    Antirheumatic coverage

    JAK inhibitors and related antirheumatic agents

    Antirheumatic specialty management: Select JAK inhibitors (e.g., RINVOQ, XELJANZ) are designated SP and require Prior Authorization and have Quantity Limits; some strengths are preferred for specific diagnoses.product‑specific QL

    Examples: RINVOQ formulations listed with SP, PA, QL per indication.

    Apremilast (Otezla) coverage

    PDE4 inhibitors (apremilast)

    Apremilast requirements: Apremilast (Otezla) products are designated SP and require Prior Authorization and Quantity Limits (e.g., 55 tabs every 28 days or product‑specific pack counts).55 tabs/28 days (typical)

    Preferred for Psoriasis and Psoriatic Arthritis per formulary notes.

    Low-dose aspirin coverage

    Aspirin 81 mg

    Preeclampsia prevention coverage: Aspirin 81 mg is covered at $0 copay for members capable of pregnancy aged 12‑59 years who are at risk for preeclampsia.Age 12‑59, pregnancy‑capable and at risk

    Otherwise aspirin 81 mg is not covered under the outpatient formulary.

    Opioid product controls

    Opioid analgesics

    Opioid controls: Opioid products are subject to Quantity Limits and Prior Authorization for certain strengths; initial supply restrictions apply (commonly a 7‑day limit for adults and a 3‑day limit for members age 19 or younger).Initial 7‑day adult / 3‑day if age ≤19

    High‑strength fentanyl patches and certain ER products require PA or PA** and may be subject to ST.

    Covered with Criteria

    Coverage is product-specific with tiering and utilization controls. Generally covered when formulary rules (PA/QL/ST) and age limits are met.

    General coverage conditions: Coverage requires the drug be listed on the Formulary AND prescribed within specified Quantity Limits AND Prior Authorization obtained when required (including for high‑strength formulations) AND initial supply limits observed.See product entries for specific QL and initial limits

    Applies broadly across opioid and combination analgesic entries.

    Age-Based Exclusions / Limits

    Products not available for certain pediatric ages.

    Pediatric availability limits: Certain formulations are not available for members under age 12 OR have shortened initial supply limits for members age 19 or younger.Not available under age 12 for specified products; initial 3‑day limit if age ≤19

    Examples include selected tramadol ER and some combination products.

    Formulary coverage with utilization management

    Coverage is provided according to drug tier but subject to the following utilization management controls where specified.

    Tier and utilization controls: Drugs carry Drug Tier assignments and may be managed with PA, ST, QL, MO, or SP flags; high‑strength formulations often require PA and some products require ST prior to coverage.Product‑specific

    Providers should consult the Formulary entry for exact controls per product and strength.

    Buprenorphine/Buprenorphine-naloxone products

    Coverage varies by formulation and strength with explicit PA/QL rules.

    Buprenorphine films (BELBUCA): BELBUCA films have Quantity Limits (commonly 60 films every 25 days) and require PA for higher strengths; highest strengths explicitly require PA.60 films/25 days (typical)

    High strengths (e.g., 600 mcg and above) require PA.

    Buprenorphine transdermal patches listed with QL (4 patches every month); higher strength patches (15–20 mcg/hr) require PA.4 patches/month

    Some patches are also subject to ST.

    Opioid combination analgesics

    Immediate coverage subject to limits and age‑based initial fill rules.

    Combination analgesic limits: Combination opioid products (hydrocodone/acetaminophen, oxycodone/acetaminophen, tramadol combos, butalbital combinations) have specified QLs and are subject to initial 7‑day limits for adults and 3‑day limits for members age 19 or younger; some are not available under age 12.See product QL (per 25 days) and initial limits

    Examples: TREZIX and other combination caps with QL (300 caps/25 days) or 48 caps/25 days for certain butalbital combos.

    Formulary coverage with quantity limits

    Coverage and limits are presented per drug and formulation with drug tier and quantity limit rules:

    Formulary listing with QL measurement period: Each drug/formulation entry includes a Drug Tier and COVERAGE REQUIREMENTS AND LIMITS (often QL with a numeric allowance over a measurement period, commonly every 75 days).Quantity measurement period: commonly every 75 days

    Examples include QL (3 inhalers every 75 days), QL (720 mL every 75 days), QL (9 inhalers every 75 days).

    General coverage determination

    Coverage is determined per product with assigned drug tier and coverage requirement flags; drugs are covered subject to those flags and quantity limits where specified.

    Formulary entry governs coverage: Coverage depends on the listed Drug Tier and COVERAGE REQUIREMENTS AND LIMITS flags (examples: MO, PA, SP, QL); providers must meet those product‑level requirements for coverage.

    Some entries marked MO indicate managed/maintenance handling; PA flags require pre‑approval.

    Product-level coverage flags

    Coverage and utilization management flags applied at product level

    Coverage flags (PA/MO/QL/SP/ST): Products are assigned a Drug Tier and may carry flags such as PA, MO, QL, SP, or ST; coverage is contingent on satisfying the listed flag requirements for the specific product and strength.

    Examples: RELGAABI listed with PA and MO; ZURZUVAE listed SP, PA, QL.

    Formulary listing with managed coverage

    Coverage stance is presented per drug entry with tier and 'COVERAGE REQUIREMENTS AND LIMITS' shorthand.

    Managed coverage notation: Many formulary entries display 'MO' indicating managed/maintenance handling; entries may also show PA, QL, SP. Requests not meeting these flags may be denied.

    Providers should include drug name, strength, quantity, and indication on PA requests as listed in the Formulary.

    Formulary coverage entries

    Coverage and utilization flags for listed drugs — considered covered subject to indicated PA, MO, and QL requirements

    GLP‑1 and incretin agents: Multiple GLP‑1 receptor agonists (tirzepatide MOUNJARO, semaglutide OZEMPIC/RYBELSUS, dulaglutide TRULICITY) are listed with PA and/or MO flags; PA is commonly required for these agents.

    Refer to each product entry for exact PA/MO designation and QL where present.

    Insulin products: Numerous insulin formulations are listed with MO (managed) flags and some branded injections note RELION products as not covered.

    See Formulary lines for RELION not covered statements and product‑level MO flags.

    This Formulary is the Sharp Health Plan electronic Prescription Drug List and is subject to change; all prior versions are no longer in effect. Providers and pharmacies must use the online formulary for current coverage and member cost-sharing information. Exclusions and limitations to the outpatient prescription drug benefit are listed in the Formulary and Member Handbook and apply as described; failure to adhere to current formulary requirements may result in noncoverage or different cost sharing.

    Drugs and supplies that fall within exclusions for the outpatient prescription drug benefit as described in the Member Handbook are not eligible under the pharmacy benefit. Examples include physician‑administered or self‑injectable drugs that are covered under the Medical Benefit, and items excluded by the plan such as certain medical devices or office‑administered products; refer to the Member Handbook for full details on benefit carve‑outs and coverage responsibility.

    The Plan does not cover drugs prescribed solely for cosmetic purposes, hair loss, sexual dysfunction, athletic performance, or anti‑aging for cosmetic reasons. Drugs prescribed only to shorten the duration of the common cold, prescription replacements for lost or stolen drugs, and certain products for non‑covered procedures by non‑contracting providers are also excluded. Several combination analgesic products and butalbital combinations are explicitly noted as not available under age 12 in the formulary entries where indicated.

    When a generic equivalent exists, Sharp Health Plan will require dispensing of the generic and does not cover the brand‑name equivalent unless a prior authorization documents medical necessity. Interchangeable biologic substitution may also be required unless prior authorization for the reference product demonstrates medical necessity.

    Certain generic amphetamine products and many stimulant agents carry utilization controls that include prior authorization and quantity limits; in particular, many listed amphetamine generics require PA for members age ≥ 19 (age‑based PA) as noted on the formulary.

    Low‑dose aspirin (81 mg chewable or delayed‑release) is generally not covered except for members who are capable of pregnancy aged 12–59 years at risk for preeclampsia, for whom the formulary provides a $0 copay benefit for aspirin 81 mg.

    Selected tramadol extended‑release formulations and some opioid combination products are explicitly listed as Not available under age 12. Age‑based initial supply limits also apply for many controlled combination analgesics (standard initial 7‑day supply for adults; initial 3‑day supply for members age 19 or younger) as shown in the formulary entries.

    Formulary Listings and Code Tables

    Covered Prescription Drugs (alphabetical index excerpts)mixedCovered
    No codes listed
    Covered Prescription Drugs (index references)mixedCovered
    No codes listed
    Step Therapy Groups referencedmixed
    2219-MOPIOID ER Step Therapy Group identifier
    1358-EOPIOID IR COMBO PRODUCTS Step Therapy Group identifier
    Amphetamine generic products with PA/QLmixedCovered
    AMPHETAMINE sulfate tab 5 mggeneric amphetamine sulfate tab 5 mg (PA, QL (360 tabs every 75 days); PA required for age >=19)
    AMPHETAMINE sulfate tab 10 mggeneric amphetamine sulfate tab 10 mg (PA, QL (360 tabs every 75 days); PA required for age >=19)
    AMPHETAMINE ER disintegrating tab 3.1 mggeneric amphetamine extended release disintegrating 3.1 mg (PA, QL (180 tabs every 75 days); PA required for age >=19)
    AMPHETAMINE ER disintegrating tab 6.3 mggeneric amphetamine extended release disintegrating 6.3 mg (PA, QL (180 tabs every 75 days); PA required for age >=19)
    AMPHETAMINE ER disintegrating tab 9.4 mggeneric amphetamine extended release disintegrating 9.4 mg (PA, QL (180 tabs every 75 days); PA required for age >=19)
    AMPHETAMINE ER disintegrating tab 12.5 mggeneric amphetamine extended release disintegrating 12.5 mg (PA, QL (90 tabs every 75 days); PA required for age >=19)
    AMPHETAMINE ER disintegrating tab 15.7 mggeneric amphetamine extended release disintegrating 15.7 mg (PA, QL; PA required for age >=19)
    Formulary stimulant and related drug listingsmixed
    WEGOVY TAB 1.5MGsemaglutide (weight management) — COVERAGE REQUIREMENTS = PA
    WEGOVY TAB 4MGsemaglutide (weight management) — COVERAGE REQUIREMENTS = PA
    WEGOVY TAB 9MGsemaglutide (weight management) — COVERAGE REQUIREMENTS = PA
    WEGOVY TAB 25MGsemaglutide (weight management) — COVERAGE REQUIREMENTS = PA, MO
    atomoxetine hcl cap (various strengths)atomoxetine HCl — COVERAGE REQUIREMENTS = PA, QL (360 caps every 75 days); PA required for age >=19
    AZSTARYS CAP (various strengths)serdexmethylphenidate chloride-dexmethylphenidate HCl — COVERAGE REQUIREMENTS = PA, QL (90 caps every 75 days)
    SUNOSI TAB 75MGsolriamfetol HCl
    SUNOSI TAB 150MGsolriamfetol HCl
    WAKIX TAB 4.45MGpitolisant HCl
    WAKIX TAB 17.8MGpitolisant HCl — COVERAGE REQUIREMENTS = SP, PA, QL (2 tabs every 1 day)
    1–10 of 16
    1/2
    Stimulant products (methylphenidate)mixedCovered
    methylphenidate hcl tab er diffusion 27 mgmethylphenidate ER diffusion 27 mg — COVERAGE REQUIREMENTS = PA, QL (180 tabs every 75 days); PA required for age >=19
    methylphenidate hcl tab er diffusion 36 mgmethylphenidate ER diffusion 36 mg — COVERAGE REQUIREMENTS = PA, QL (180 tabs every 75 days); PA required for age >=19
    methylphenidate hcl tab er diffusion 54 mgmethylphenidate ER diffusion 54 mg — COVERAGE REQUIREMENTS = PA, QL (90 tabs every 75 days); PA required for age >=19
    methylphenidate hcl tab er osmotic release (osm) 18 mgmethylphenidate OROS 18 mg — COVERAGE REQUIREMENTS = PA, QL (180 tabs every 75 days); PA required for age >=19
    methylphenidate hcl tab er osmotic release (osm) 27 mgmethylphenidate OROS 27 mg — COVERAGE REQUIREMENTS = PA, QL (180 tabs every 75 days); PA required for age >=19
    methylphenidate hcl tab er osmotic release (osm) 36 mgmethylphenidate OROS 36 mg — COVERAGE REQUIREMENTS = PA, QL (180 tabs every 75 days); PA required for age >=19
    methylphenidate hcl tab er osmotic release (osm) 54 mgmethylphenidate OROS 54 mg — COVERAGE REQUIREMENTS = PA, QL (90 tabs every 75 days); PA required for age >=19
    methylphenidate hcl tab er osmotic release (osm) 72 mgmethylphenidate OROS 72 mg — COVERAGE REQUIREMENTS = PA, QL (90 tabs every 75 days); PA required for age >=19
    methylphenidate td patch 10 mg/9hrmethylphenidate transdermal patch 10 mg/9hr — COVERAGE REQUIREMENTS = PA, QL (90 patches every 75 days); PA required for age >=19
    methylphenidate td patch 15 mg/9hrmethylphenidate transdermal patch 15 mg/9hr — COVERAGE REQUIREMENTS = PA, QL (90 patches every 75 days); PA required for age >=19
    1–10 of 12
    1/2
    Wakefulness agentsmixedCovered
    modafinil tab 100 mgmodafinil 100 mg tablet — COVERAGE REQUIREMENTS = PA, MO
    modafinil tab 200 mgmodafinil 200 mg tablet — COVERAGE REQUIREMENTS = PA, MO
    Allergen immunotherapy productsmixedCovered
    GRASTEK SUB 2800BAUtimothy grass pollen allergen extract (Grastek) — COVERAGE REQUIREMENTS = PA, MO
    ODACTRA SUBdust mite mixed allergen extract (Odactra) — COVERAGE REQUIREMENTS = PA, MO
    ORALAIR SUB 300 IRgrass mixed pollens allergen extract (Oralair) — COVERAGE REQUIREMENTS = PA, MO
    RAGWITEK SUBshort ragweed pollen allergen extract (Ragwitek) — COVERAGE REQUIREMENTS = PA, MO
    Antirheumatic - JAK inhibitorsmixedCovered
    RINVOQ LQ SOL 1MG/MLupadacitinib solution 1 mg/mL — COVERAGE REQUIREMENTS = SP, PA, QL (12 mL every 1 day)
    RINVOQ TAB 15MG ERupadacitinib 15 mg ER tablet — COVERAGE REQUIREMENTS = SP, PA, QL (1 tab every 1 day)
    RINVOQ TAB 30MG ERupadacitinib 30 mg ER tablet — COVERAGE REQUIREMENTS = SP, PA, QL (1 tab every 1 day)
    RINVOQ TAB 45MG ERupadacitinib 45 mg ER tablet — COVERAGE REQUIREMENTS = SP, PA, QL (84 tabs every 84 days)
    XELJANZ SOL 1MG/MLtofacitinib solution 1 mg/mL — COVERAGE REQUIREMENTS = SP, PA, QL (10 mL every 1 day)
    XELJANZ TAB 5MGtofacitinib 5 mg tablet — COVERAGE REQUIREMENTS = SP, PA, QL (2 tabs every 1 day)
    XELJANZ TAB 10MGtofacitinib 10 mg tablet — COVERAGE REQUIREMENTS = SP, PA, QL (2 tabs every 1 day)
    XELJANZ XR TAB 11MGtofacitinib XR 11 mg tablet — COVERAGE REQUIREMENTS = SP, PA, QL (1 tab every 1 day)
    PDE4 inhibitors (apremilast)mixedCovered
    OTEZLA TAB 20MGapremilast 20 mg tablet — COVERAGE REQUIREMENTS = SP, PA, QL (55 tabs every 28 days)
    OTEZLA TAB 30MGapremilast 30 mg tablet — COVERAGE REQUIREMENTS = SP, PA, QL (2 tabs every 1 day)
    OTEZLA XR TAB 75MGapremilast XR 75 mg tablet — COVERAGE REQUIREMENTS = SP, PA, QL (1 tab every 1 day)
    Aspirin (low dose)mixedCovered
    Aspirin Chew Tab 81 mgaspirin chewable 81 mg — COVERAGE REQUIREMENTS = MO, QL (100 tabs every 30 days); $0 copay for members capable of pregnancy age 12-59 at risk for preeclampsia
    aspirin tab delayed release 81 mgaspirin delayed-release 81 mg — COVERAGE REQUIREMENTS = MO, QL (100 tabs every 30 days); $0 copay for members capable of pregnancy age 12-59 at risk for preeclampsia
    Opioid productsmixedCovered
    fentanyl td patch 72hr 12 mcg/hrfentanyl transdermal patch 12 mcg/hr — COVERAGE REQUIREMENTS = ST, QL (10 patches every 25 days); PA**
    fentanyl td patch 72hr 25 mcg/hrfentanyl transdermal patch 25 mcg/hr — COVERAGE REQUIREMENTS = ST, QL (10 patches every 25 days); PA**
    fentanyl td patch 72hr 37.5 mcg/hrfentanyl transdermal patch 37.5 mcg/hr — COVERAGE REQUIREMENTS = ST, QL (10 patches every 25 days); PA**
    fentanyl td patch 72hr 50 mcg/hrfentanyl transdermal patch 50 mcg/hr — COVERAGE REQUIREMENTS = PA; High Strength Requires PA
    hydrocodone bitartrate cap er 12hr 10 mghydrocodone ER 10 mg cap (12 hr) — COVERAGE REQUIREMENTS = ST, QL (60 caps every 25 days); PA**
    Opioid and Opioid Combination ProductsmixedCovered
    codeine sulfate tab 30 mggeneric codeine sulfate 30 mg tablet — COVERAGE REQUIREMENTS = PA, QL (42 tabs every 25 days); initial 7-day limit; if age <=19 initial 3-day limit
    hydrocodone-acetaminophen soln 7.5-325 mg/15mlhydrocodone-acetaminophen solution — COVERAGE REQUIREMENTS = PA, QL (2700 mL every 25 days); subject to initial limits
    acetaminophen w/ codeine soln 120-12 mg/5mlacetaminophen with codeine solution — COVERAGE REQUIREMENTS = ST, QL (2700 mL every 25 days); PA**; subject to initial limits
    acetaminophen w/ codeine tab 300-15 mgacetaminophen with codeine tab 300-15 mg — COVERAGE REQUIREMENTS = ST, QL (400 tabs every 25 days); PA**; subject to initial limits
    acetaminophen w/ codeine tab 300-30 mgacetaminophen with codeine tab 300-30 mg — COVERAGE REQUIREMENTS = ST, QL (360 tabs every 25 days); PA**; subject to initial limits
    acetaminophen w/ codeine tab 300-60 mgacetaminophen with codeine tab 300-60 mg — COVERAGE REQUIREMENTS = ST, QL (180 tabs every 25 days); PA**; subject to initial limits
    acetaminophen-caffeine-dihydrocodeine cap 320.5-30-16 mgacetaminophen-caffeine-dihydrocodeine cap — COVERAGE REQUIREMENTS = ST, QL (300 caps every 25 days); PA**; subject to initial limits
    Butalbital-Acetaminophen-Caffeine capbutalbital combinations — COVERAGE REQUIREMENTS = QL (48 caps every 25 days); Not available under age 12
    TREZIX (acetaminophen-caffeine-dihydrocodeine)TREZIX cap 320.5-30-16 mg — COVERAGE REQUIREMENTS = ST, QL (300 caps every 25 days); PA**; subject to initial limits
    Quantity limit codes (formulary)mixed
    QL (150 tabs every 25 days)Quantity limit for alprazolam formulations as listed
    QL (90 tabs every 25 days)Quantity limit for alprazolam ER 3 mg
    QL (360 caps every 25 days)Quantity limit for chlordiazepoxide caps
    QL (240 mL every 25 days)Quantity limit for diazepam concentrate
    QL (1200 mL every 25 days)Quantity limit for diazepam oral solution
    QL (150 mL every 25 days)Quantity limit for lorazepam concentrate/tabs (example)
    Inhalation product quantity limitsmixed
    QL (720 mL every 75 days)Quantity limit for cromolyn sodium nebule
    QL (6 inhalers every 75 days)Quantity limit for ipratropium HFA inhaler
    QL (938 mL every 75 days)Quantity limit for ipratropium inhalation solution
    QL (90 caps every 75 days)Quantity limit for Spiriva HandiHaler caps
    QL (3 inhalers every 75 days)Quantity limit for Spiriva Respimat inhalers
    QL (270 mL every 75 days)Quantity limit for revefenacin (YUPELRI) nebule
    Anticoagulants / Thrombin inhibitorsmixed
    rivaroxaban tab 2.5 mggeneric rivaroxaban — COVERAGE REQUIREMENTS = MO
    XARELTO TAB 10MGrivaroxaban — COVERAGE REQUIREMENTS = MO
    XARELTO TAB 15MGrivaroxaban — COVERAGE REQUIREMENTS = MO
    XARELTO TAB 20MGrivaroxaban — COVERAGE REQUIREMENTS = MO
    XARELTO SUS 1MG/MLrivaroxaban suspension — COVERAGE REQUIREMENTS = MO
    Thrombin inhibitors (dabigatran)mixed
    dabigatran etexilate mesylate cap 75 mgdabigatran — COVERAGE REQUIREMENTS = MO
    dabigatran etexilate mesylate cap 110 mgdabigatran — COVERAGE REQUIREMENTS = MO
    dabigatran etexilate mesylate cap 150 mgdabigatran — COVERAGE REQUIREMENTS = MO
    Anticonvulsants - benzodiazepines (clobazam)mixedCovered
    clobazam suspension 2.5 mg/mlclobazam suspension — COVERAGE REQUIREMENTS = MO
    clobazam tab 10 mgclobazam 10 mg tablet — COVERAGE REQUIREMENTS = MO
    clobazam tab 20 mgclobazam 20 mg tablet — COVERAGE REQUIREMENTS = MO
    Clonazepam formulations with QLmixedCovered
    clonazepam orally disintegrating tab 0.125 mggeneric clonazepam ODT 0.125 mg — COVERAGE REQUIREMENTS = QL (300 tabs every 25 days)
    clonazepam orally disintegrating tab 0.25 mgCOVERAGE REQUIREMENTS = QL (300 tabs every 25 days)
    clonazepam orally disintegrating tab 0.5 mgCOVERAGE REQUIREMENTS = QL (300 tabs every 25 days)
    clonazepam orally disintegrating tab 1 mgCOVERAGE REQUIREMENTS = QL (300 tabs every 25 days)
    clonazepam orally disintegrating tab 2 mgCOVERAGE REQUIREMENTS = QL (300 tabs every 25 days)
    clonazepam tab 0.5 mgCOVERAGE REQUIREMENTS = QL (300 tabs every 25 days)
    clonazepam tab 1 mgCOVERAGE REQUIREMENTS = QL (300 tabs every 25 days)
    clonazepam tab 2 mgCOVERAGE REQUIREMENTS = QL (300 tabs every 25 days)
    Rescue/benzodiazepine rescue productsmixed
    diazepam rectal gel delivery system 2.5 mgdiazepam rectal gel — DRUG TIER = 1
    diazepam rectal gel delivery system 10 mgdiazepam rectal gel — DRUG TIER = 1
    diazepam rectal gel delivery system 20 mgdiazepam rectal gel — DRUG TIER = 1
    NAYZILAM SPR 5MGmidazolam spray — DRUG TIER = 2
    VALTOCO SPR 5MGdiazepam nasal spray — DRUG TIER = 2
    VALTOCO SPR 15MGdiazepam nasal spray — DRUG TIER = 2
    Brivaracetam productsmixed
    brivaracetam oral soln 10 mg/mlbrivaracetam oral solution — AND LIMITS = MO (table shows numeric limits)
    BRIVIACT SOL 10MG/MLbrand brivaracetam solution — AND LIMITS = 2, MO
    BRIVIACT TAB 10MGbrivaracetam tablet — AND LIMITS = 2, MO
    Carbamazepine / eslicarbazepinemixed
    carbamazepine cap er 12hr 100 mgcarbamazepine — AND LIMITS = MO
    CARBATROL CAP 100MGbrand carbamazepine — AND LIMITS = 2, MO
    eslicarbazepine acetate tab 200 mgeslicarbazepine acetate — AND LIMITS = MO
    Gabapentin / lacosamidemixed
    gabapentin cap 100 mggabapentin — AND LIMITS = MO
    lacosamide oral solution 10 mg/mllacosamide solution — AND LIMITS = MO
    lacosamide tab 50 mglacosamide tablet — AND LIMITS = MO
    Broad anticonvulsant entries (lamotrigine, levetiracetam, oxcarbazepine, pregabalin, rufinamide, topiramate, etc.)mixedCovered
    lamotrigine various tabs and starter kitsmultiple lamotrigine formulations — COVERAGE REQUIREMENTS = MO
    levetiracetam oral soln 100 mg/ml and tabslevetiracetam formulations — COVERAGE REQUIREMENTS = MO
    oxcarbazepine susp 300 mg/5ml and tabsoxcarbazepine — COVERAGE REQUIREMENTS = MO
    pregabalin cap 25–300 mg and solnpregabalin formulations — COVERAGE REQUIREMENTS = MO
    RELGAABI CAP 200MGbrand gabapentin 200 mg — COVERAGE REQUIREMENTS = PA, MO
    rufinamide susp 40 mg/ml and tabs 200/400 mgrufinamide — COVERAGE REQUIREMENTS = MO
    topiramate ER caps and oral solntopiramate formulations — COVERAGE REQUIREMENTS = MO
    Formulary drug entries (partial)mixed
    RELGAABI CAP 200MG(brand gabapentin) — COVERAGE REQUIREMENTS = PA, MO
    pregabalin cap 75 mgpregabalin capsule — COVERAGE REQUIREMENTS = MO
    XCOPRI TAB 25MGcenobamate — COVERAGE REQUIREMENTS = MO
    ZURZUVAE CAP 20MGzuranolone — COVERAGE REQUIREMENTS = SP, PA, QL (2 caps every 1 day)
    Listed antidepressants (partial)mixed
    TRINTELLIX TAB 5MGvortioxetine hbr — COVERAGE REQUIREMENTS = MO
    TRINTELLIX TAB 10MGvortioxetine hbr — COVERAGE REQUIREMENTS = MO
    TRINTELLIX TAB 20MGvortioxetine hbr — COVERAGE REQUIREMENTS = MO
    vilazodone hcl tab 10 mgvilazodone — COVERAGE REQUIREMENTS = MO
    vilazodone hcl tab 20 mgvilazodone — COVERAGE REQUIREMENTS = MO
    vilazodone hcl tab 40 mgvilazodone — COVERAGE REQUIREMENTS = MO
    SNRIs and related agentsmixed
    desvenlafaxine succinate tab er 24hr 25 mgdesvenlafaxine — COVERAGE REQUIREMENTS = MO
    desvenlafaxine succinate tab er 24hr 50 mgdesvenlafaxine — COVERAGE REQUIREMENTS = MO
    desvenlafaxine succinate tab er 24hr 100 mgdesvenlafaxine — COVERAGE REQUIREMENTS = MO
    duloxetine hcl enteric coated pellets cap 20 mgduloxetine — COVERAGE REQUIREMENTS = MO
    duloxetine hcl ... 60 mgduloxetine — COVERAGE REQUIREMENTS = MO
    Venlafaxine and tricyclic agents (partial)mixed
    venlafaxine hcl cap er 24hr 37.5 mgvenlafaxine — COVERAGE REQUIREMENTS = MO
    venlafaxine hcl cap er 24hr 75 mgvenlafaxine — COVERAGE REQUIREMENTS = MO
    venlafaxine hcl cap er 24hr 150 mgvenlafaxine — COVERAGE REQUIREMENTS = MO
    amitriptyline hcl tab 10 mgamitriptyline — COVERAGE REQUIREMENTS = MO
    amitriptyline hcl tab 25 mgamitriptyline — COVERAGE REQUIREMENTS = MO
    amitriptyline hcl tab 50 mgamitriptyline — COVERAGE REQUIREMENTS = MO
    Alpha-glucosidase inhibitorsmixed
    acarbose tab 25 mgacarbose — COVERAGE REQUIREMENTS = MO
    acarbose tab 50 mgacarbose — COVERAGE REQUIREMENTS = MO
    acarbose tab 100 mgacarbose — COVERAGE REQUIREMENTS = MO
    miglitol tab 25 mgmiglitol — COVERAGE REQUIREMENTS = MO
    miglitol tab 50 mgmiglitol — COVERAGE REQUIREMENTS = MO
    miglitol tab 100 mgmiglitol — COVERAGE REQUIREMENTS = MO
    Combination antidiabetic productsmixed
    GLYXAMBI TAB 10-5 MGempagliflozin-linagliptin (brand) — COVERAGE REQUIREMENTS = MO
    GLYXAMBI TAB 25-5 MGempagliflozin-linagliptin (brand) — COVERAGE REQUIREMENTS = MO
    SOLIQUA INJ 100/33insulin glargine-lixisenatide — COVERAGE REQUIREMENTS = MO
    SYNJARDY TAB (various strengths)empagliflozin-metformin — COVERAGE REQUIREMENTS = MO
    TRIJARDY XR TABempagliflozin-linagliptin-metformin — COVERAGE REQUIREMENTS = MO
    Biguanides and glucagon productsmixed
    metformin hcl oral soln 500 mg/5mlmetformin solution — COVERAGE REQUIREMENTS = MO
    metformin hcl tab 500 mgmetformin — COVERAGE REQUIREMENTS = MO
    metformin hcl tab 850 mgmetformin — COVERAGE REQUIREMENTS = MO
    BAQSIMI ONE POW 3MG/DOSEBAQSIMI glucagon — COVERAGE REQUIREMENTS = (listed)
    GVOKE HYPO 1 INJ 0.5/.1MLGVOKE glucagon injection — COVERAGE REQUIREMENTS = (listed)
    Quantity limits and special supply rulesmixed
    QL (12 tabs every 21 days)Granisetron tab quantity limit as listed
    QL (200 mL every 21 days)Ondansetron oral solution quantity limit
    QL (18 tabs every 21 days)Ondansetron tablet/disintegrating tablet quantity limit
    QL (2 patches every 21 days)Sancuso patch quantity limit
    QL (3 caps every 180 days)Aprepitant capsule 40 mg limit
    QL (4 caps every 21 days)Aprepitant capsule 80 mg limit
    QL (2 caps every 21 days)Aprepitant capsule 125 mg limit
    QL (6 caps every 21 days)Aprepitant therapy pack limit
    QL (20 packets every 5 days)Vistogard pak limit
    QL (4 sprays every 25 days)Naloxone nasal spray limit
    1–10 of 11
    1/2
    Oral anti-cancer cost cap
    Oral anti-cancer copay cap$250 per individual prescription (up to 30-day supply)
    Measurement periodUp to a 30-day supply per individual prescription
    ApplicabilityApplies to drugs with OAC designation (oral anti-cancer drugs)
    Immediate-release opioid fill threshold
    IR opioid fill thresholdCumulative ≥ 7 days' supply within the past 90 days
    Lookback period90 days
    PurposeUsed to satisfy step therapy requirement for ER opioids (OPIOID ER 2219-M)
    Extended-release opioid fill threshold
    ER opioid fill thresholdCumulative ≥ 30 days' supply within the past 90 days
    Lookback period90 days
    PurposeUsed to satisfy step therapy requirement for ER opioid coverage (OPIOID ER 2219-M)
    Amphetamine quantity-limit examples
    Amphetamine QL example — high count360 tablets every 75 days (product-dependent)
    Amphetamine QL example — mid count180 tablets every 75 days (product-dependent)
    Amphetamine QL example — low count90 tablets every 75 days (product-dependent)
    Opioid prior exposure thresholds
    Opioid prior exposure — IRCumulative ≥ 7 days' supply of an immediate‑release opioid within the past 90 days
    Opioid prior exposure — EROr, cumulative ≥ 30 days' supply of an extended‑release opioid within the past 90 days
    UseSatisfies step therapy requirement for OPIOID ER group (2219‑M)

    Provider Steps, Prior Authorization and Documentation

    Prior Authorization

    Follow formulary PA/coverage requirement process

    The formulary includes sections describing Prior Authorization (PA), Step Therapy (ST), Quantity Limits (QL), Medication Override (MO), Specialty (SP), and other coverage requirement flags; providers must follow the specified process in the formulary to obtain coverage.

    • PA, PA** require prior authorization based on clinical criteria; PA** applies when step therapy is not met
    • QL limits coverage to a specified quantity per prescription/time period; PA required for other quantities
    • ST requires trial of specified agents before coverage; exceptions can be requested
    • MO indicates maintenance/mail-order eligibility; SP indicates specialty pharmacy handling
    Prior Authorization

    Obtain prior authorization for PA / PA** drugs

    Drugs flagged 'PA' or 'PA**' require the Prescribing Provider to submit a Prior Authorization request; PA** means PA is required if Step Therapy criteria have not been met.

    • PA decisions: 72 hours for non‑urgent requests; 24 hours for urgent/exigent requests
    • PA** applies when Step Therapy is unmet; provider may request PA to bypass steps with medical justification
    Prior Authorization

    Submit PA via phone, fax, or electronic form with supporting information

    Prescribing providers must request Prior Authorization by phone, fax, or electronic Prior Authorization form and submit all required supporting clinical information for review.

    • Submit complete supporting documentation to avoid delays (plan will notify within 72 hours (24 hours exigent) if additional info is needed)
    • Decisions rendered within 72 hours non‑urgent or 24 hours urgent/exigent
    Prior Authorization

    Obtain PA and observe QLs for amphetamine products (age ≥19)

    Many generic amphetamine products require prior authorization for members age ≥19 and are subject to quantity limits; providers must obtain PA and document age and justification when prescribing for adults.

    • Examples of QL include 360 tabs every 75 days, 180 tabs every 75 days, 90 tabs every 75 days (product dependent)
    • PA is required for age greater than or equal to 19 for multiple amphetamine entries
    Step Therapy

    Follow opioid ER step‑therapy exposure requirements

    Step Therapy applies to certain extended‑release opioid products (OPIOID ER Group 2219‑M); coverage requires documented prior opioid exposure per the formulary step criteria.

    • Coverage for OPIOID ER 2219‑M is allowed if member has cumulative ≥7 days IR opioid in past 90 days OR cumulative ≥30 days ER opioid in past 90 days
    • If prior exposure not met, limited 7‑day IR supply may be provided per OPIOID IR COMBO PRODUCTS 1358‑E
    Prior Authorization

    Obtain PA for listed stimulants and selected agents

    Many stimulant and related agents listed (amphetamines, methylphenidate, atomoxetine, select anti‑obesity agents) require prior authorization; obtain PA before prescribing when the formulary flags PA.

    • Examples include WEGOVY and orlistat (PA for anti‑obesity agents) and numerous stimulant formulations flagged PA
    • Some entries also include MO or QL in addition to PA
    Documentation Required

    Document prior opioid exposure to meet ER opioid PA/ST

    Coverage for specified ER opioid products requires prior opioid exposure as defined in the opioid step therapy rules; providers must document pharmacy fill history demonstrating required exposure.

    • Required prior exposure: cumulative ≥7 days IR within past 90 days or cumulative ≥30 days ER within past 90 days
    • If no prior opioid supply, coverage may be limited to a 7‑day IR supply (OPIOID IR COMBO PRODUCTS 1358‑E)
    Prior Authorization

    Obtain PA for listed stimulant/related products (WEGOVY, atomoxetine, methylphenidate)

    Numerous stimulant and related agents (including semaglutide/WEGOVY, atomoxetine, methylphenidate/dexmethylphenidate, AZSTARYS, QELBREE) list PA and often QL or MO; obtain PA and document clinical rationale.

    • Atomoxetine example QL: 360 caps every 75 days
    • Methylphenidate/dexmethylphenidate entries specify PA and QL and PA required for age ≥19
    Prior Authorization

    PA and QL required for methylphenidate ER/patch products (age ≥19)

    Many methylphenidate ER/OROS formulations and transdermal patches require prior authorization for members age ≥19 and are subject to quantity limits (e.g., 90 or 180 units per 75 days); include age and quantity on PA requests.

    • Examples: methylphenidate OSM/ER entries show PA, QL (90–180 units every 75 days)
    • PA required for age greater than or equal to 19
    Prior Authorization

    Submit PA for select JAK inhibitors (SP, PA, QL)

    Select JAK inhibitor products (RINVOQ, XELJANZ) are specialty (SP) designated and require prior authorization and quantity limits; submit specialty PA documentation when requesting these agents.

    • RINVOQ and XELJANZ entries: SP, PA, QL (e.g., RINVOQ QL and preferred strengths noted)
    • Provide indication and product‑specific information with PA for specialty agents
    Prior Authorization

    Obtain PA for opioid products and high‑strength formulations

    Many opioid products—especially high‑strength formulations—require prior authorization or are subject to step therapy; verify PA/ST flags and obtain authorization when required before dispensing.

    • High‑strength fentanyl patches and some hydrocodone ER products are marked ST and/or require PA** or PA
    • Initial supply limits (7‑day adult; 3‑day if age ≤19) apply to many opioid entries
    Prior Authorization

    Verify PA for specified high‑risk products (opioid combos, buprenorphine)

    Numerous listed products require prior authorization including certain opioid combinations, high‑strength buprenorphine films/patches, and other controlled products; confirm PA flags before prescribing.

    • BELBUCA high strengths require PA; buprenorphine TD patches >15 mcg/hr require PA
    • Opioid combinations often show ST, QL, and PA**
    Prior Authorization

    Follow MO/MANAGED coverage guidance and PA when indicated

    Products marked with 'MO' or other coverage requirement flags may indicate managed coverage and prior authorization or medical necessity review; providers should follow product‑level guidance and include required documentation on PA requests.

    • Many entries show COVERAGE REQUIREMENTS AND LIMITS = MO indicating managed coverage controls
    • Requests that do not meet MO requirements may be limited or denied
    Billing Rule

    Request PA when qty exceeds QL or for higher‑tier brands

    Branded products with QL or tiering may trigger PA when requests exceed QL or are for nonpreferred tiers; obtain PA for quantities above listed limits and include justification.

    • PA may be required for requests exceeding QL or for nonpreferred brand tiers
    • Document clinical necessity when requesting quantities above QL
    Prior Authorization

    Obtain PA for products explicitly flagged PA (examples: RELGAABI)

    Medications flagged 'PA' (e.g., RELGAABI cap 200 mg) require prior authorization before coverage; providers must obtain PA to avoid coverage denials.

    • RELGAABI entry explicitly lists PA and MO in coverage flags
    • Obtain PA prior to dispensing to prevent denial
    Prior Authorization

    Confirm and obtain PA for specified brand entries

    Certain brand entries list PA in their coverage flags (example: RELGAABI cap 200 mg); verify product‑level flags and submit PA for brand‑specific entries as required.

    • Check formulary line for brand entries indicating PA
    • Submit PA with required documentation for brand‑specific coverage
    Prior Authorization

    Submit SP/PA with indication and QL justification for zuranolone

    ZURZUVAE (zuranolone) entries are marked SP, PA, and have QL (e.g., 2 caps every 1 day or 1 cap for 30 mg); prior authorization must document the indication and justify the requested quantity.

    • ZURZUVAE CAP 20/25 mg: QL 2 caps every 1 day and SP, PA flags
    • ZURZUVAE CAP 30 mg: QL 1 cap every 1 day and SP, PA flags
    Documentation Required

    Provide diagnosis and PA documentation for MO‑designated drugs

    Products labeled 'COVERAGE REQUIREMENTS AND LIMITS = MO' indicate medications subject to managed coverage or authorization review; providers should include diagnosis and required prior authorization forms when requesting coverage.

    • MO flag appears across multiple branded and generic products
    • Documentation expectations include indicated diagnosis and PA forms for MO‑designated items
    Prior Authorization

    Obtain PA (and respect MO) for GLP‑1/incretin agents

    Many GLP‑1 receptor agonists and oral semaglutide (MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY) require prior authorization and may also be limited by MO flags; obtain PA and follow MO limits as applicable.

    • Examples: MOUNJARO, RYBELSUS, TRULICITY entries show PA and/or MO
    • Include clinical justification and prior therapy history with PA requests for incretin agents
    Step Therapy

    Follow Step Therapy processes and request exceptions when medically necessary

    The formulary contains a Step Therapy Criteria section; Sharp Health Plan may require Step Therapy where coverage depends on prior use of alternative drugs, and providers can request Step Therapy exceptions.

    • If Step Therapy exemption is requested, submit clinical justification and supporting documentation with the Step Therapy Exception request
    • If plan fails to respond within the required timeframe, the exception is deemed granted
    Documentation Required

    Document clinical rationale for Step Therapy exceptions

    If a Step Therapy Exception is requested, providers must document why the required step is inconsistent with good professional practice and submit supporting clinical documentation; incomplete requests will be followed up within 72 hours (24 hours exigent).

    • Provide clinical rationale and relevant records to support exception requests
    • Plan will notify provider within 72 hours (24 hours exigent) if additional information is needed
    Documentation Required

    Document prior opioid fills to satisfy opioid step therapy

    To meet opioid step therapy requirements, documentation must show pharmacy fill history demonstrating either a cumulative ≥7‑day supply of an immediate‑release opioid within the past 90 days or a cumulative ≥30‑day supply of an extended‑release opioid within the past 90 days.

    • Include dates, days supplied, and drug names for prior opioid fills on PA/step therapy requests
    • If prior exposure not shown, coverage may be limited to a 7‑day IR supply
    Billing Rule

    Apply 7‑day short‑course allowance for opioid IR combos when no prior exposure

    For OPIOID IR COMBO PRODUCTS (1358‑E), coverage is allowed for up to a 7‑day supply if the member does not have at least a cumulative 7‑day supply of any opioid in the past 90 days — document this on the PA/claim.

    • Short‑course allowance is limited to up to 7 days when no prior opioid supply exists in prior 90 days
    • Include pharmacy history to demonstrate absence of recent opioid exposure
    Denial Risk

    Risk of PA denial — ensure complete clinical support

    Prior Authorization requests may be denied if supporting clinical information does not meet Sharp Health Plan clinical policies; denied requests mean coverage will not be provided unless an Appeal/Grievance is filed.

    • If PA is denied, the Member, Authorized Representative, or Prescribing Provider may file an Appeal or Grievance per formulary procedures
    • Ensure PA submissions include the clinical evidence required by plan policies to reduce denial risk
    Denial Risk

    Opioid step therapy — denial risk if prior exposure not documented

    Coverage may be denied if the member has not met opioid step therapy requirements (no record of cumulative ≥7 days IR opioid within past 90 days or cumulative ≥30 days ER opioid in past 90 days); verify and document prior fills.

    • Lack of documented prior opioid exposure will trigger denial under opioid step therapy rules
    • Provide pharmacy fill history to support prior exposure
    Denial Risk

    Amphetamine PA/QL — denial risk for age ≥19 without PA or QL exceedance

    Requests for amphetamine‑class products for members aged 19+ without required PA or exceeding quantity limits risk denial; include age and justification on PA requests.

    • Multiple amphetamine entries explicitly state PA required for age ≥19
    • Exceeding listed QL (e.g., 360 tabs/75 days) without PA may result in denial
    Denial Risk

    Adult stimulant fills — denial risk without PA

    Failure to obtain PA for many methylphenidate/amphetamine products for members aged ≥19 may result in coverage denial; verify PA requirements before dispensing adult stimulant fills.

    • Methylphenidate ER/OROS and patches list PA and QL and require PA for age ≥19
    • Providers should confirm PA prior to prescribing to adult members
    Denial Risk

    PA required for specialty antirheumatics — denial risk if missing

    Specialty (SP) antirheumatic agents and select agents (e.g., RINVOQ, XELJANZ, apremilast) require prior authorization and are subject to quantity limits; lack of PA may lead to noncoverage.

    • RINVOQ and XELJANZ entries show SP, PA, and QL; apremilast entries show SP, PA, QL (e.g., 55 tabs every 28 days)
    • Submit specialty PA documentation including diagnosis and prior therapy history
    Denial Risk

    Denial risk for QL or high‑strength requests without PA

    Requests exceeding listed quantity limits (QL) or for high‑strength products without prior authorization are subject to denial or require PA; confirm QL and PA flags before authorizing larger quantities or high strengths.

    • High‑strength formulations (e.g., BELBUCA ≥600 mcg; buprenorphine TD >15 mcg/hr) require PA
    • Requests exceeding QL (measurement periods commonly every 75 days) may be denied
    Prior Authorization

    High‑strength formulations require PA

    High‑strength formulations (e.g., higher‑strength BELBUCA films and buprenorphine patches >15 mcg/hr) explicitly require prior authorization; obtain PA before prescribing these strengths.

    • BELBUCA 600 mcg+ flagged 'PA; High Strength Requires PA'
    • Buprenorphine transdermal patches 15–20 mcg/hr flagged PA for higher strengths
    Documentation Required

    Document age and quantity for opioid initial limits and QLs

    Controlled combination analgesics and many opioid products are subject to quantity limits and initial short‑duration limits (initial 7‑day for adults; initial 3‑day for members ≤19); document patient age and quantity on PA/claim.

    • Examples: codeine QL 42 tabs every 25 days with initial 7‑day limit (3‑day if age ≤19)
    • Opioid combination products often list ST, QL, and initial supply limits
    Denial Risk

    Coverage flags (MO/PA/QL) can trigger denial if unmet

    Entries with coverage flags such as MO (managed coverage), PA, and QL can trigger coverage denials if their requirements are not met; check product‑level flags and comply before prescribing or dispensing.

    • MO‑flagged products commonly require additional documentation or PA
    • Coverage flags are attached at the product line and must be satisfied to obtain coverage
    Prior Authorization

    PA and MO limits for GLP‑1 agents — follow product guidance

    For GLP‑1/incretin agents and other MO‑flagged products, providers must follow PA and MO guidance; failure to meet PA or MO limits may result in denial.

    • MOUNJARO, RYBELSUS, TRULICITY entries show PA and/or MO
    • Include prior therapy and relevant clinical data on PA requests for incretin agents
    Billing Rule

    Verify MO limits for insulin products

    Many insulin products are marked MO; prescriptions not meeting MO (member/managed) limits may be limited or denied — verify plan‑specific insulin MO rules before dispensing.

    • RELION‑branded insulin products noted as not covered in some entries
    • Check MO flags and plan coverage details for insulin products

    Initial Therapy and Age-Based Limits

    Opioid initial therapy

    Opioid step therapy initial exposure requirements

    Opioid ER initial coverage: Member must have prior cumulative ≥7 days of IR opioid fills within past 90 days OR cumulative ≥30 days of ER opioid fills within past 90 days to obtain coverage for OPIOID ER group.IR: ≥7 days; ER: ≥30 days within past 90 days

    If criteria not met, up to a 7‑day IR supply may be covered per IR combo rules.

    Age-specific prior authorization

    Age‑specific PA: Prior Authorization is required for specified products when the member's age is greater than or equal to 19 years (applies to many stimulant and related products).age >= 19

    Documentation should include member age on PA requests.

    Initial Therapy Limits

    Initial therapy rules for many opioids include limited initial supplies and age‑based shorter limits.

    Initial supply limits: Initial opioid prescriptions are subject to a 7‑day limit for adults; if the member is age 19 or younger, an initial 3‑day limit applies where specified.7‑day (adult); 3‑day (age ≤19)

    Applies to many opioid liquids, tablets, and combination products; providers must document age to apply the shorter limit.

    Initial therapy limits

    Initial fill limits and age‑based restrictions

    Initial duration and product limits: Selected controlled products are subject to initial 7‑day limits for adults and initial 3‑day limits for members age 19 or younger; some products are explicitly Not Available under age 12.7‑day adult / 3‑day if age ≤19; Not available <12 for specified products

    Examples: many opioid combinations and certain tramadol ER products.

    Opioid initial supply limits (age-based)
    Initial opioid supply — adultsInitial 7‑day limit for adults
    Initial opioid supply — younger patientsInitial 3‑day limit if age 19 or younger
    EnforcementLimits applied at point of dispensing and referenced in product entries
    Initial supply limits (summary)
    Initial supply — standardInitial 7‑day limit for adults
    Initial supply — pediatric/young adultsInitial 3‑day limit if age 19 or younger
    DocumentationPrescriber should document patient age and indication when requesting quantities above limits
    Documentation Required

    Document age/quantity when requesting opioid supply beyond initial limits

    Initial opioid prescribing is limited (initial 7‑day supply for adults; initial 3‑day supply for members age 19 or younger); providers must document patient age and quantity when requesting coverage beyond these limits.

    • Many opioid and combination products are subject to initial supply limits at point of dispensing.
    • If requesting quantities beyond the initial limits, include justification and prior fill history with the PA.

    Step Therapy Criteria and Program Rules

    Step Therapy SectionSummary
    Formulary Step Therapy Criteria section
    The formulary contains a dedicated Step Therapy Criteria section and therapeutic-class pages where step therapy may apply; providers should refer to those sections for product-specific step requirements.
    Step Therapy RequirementImplication
    Members may be required to trial specified alternate drug(s) prior to coverage of a requested drug (ST)
    Drugs flagged PA** require prior authorization if Step Therapy criteria have not been met (i.e., PA applies when steps aren't satisfied)
    Provider Documentation RequirementAction
    When a required Step Therapy drug is inconsistent with good professional practice, the prescribing provider must submit a Step Therapy Exception request
    Provider must include justification and supporting clinical documentation with the Step Therapy Exception request; if complete the plan will decide within required timeframes or the request is deemed granted if the plan does not respond timely
    Opioid Step Therapy Exposure RequirementCoverage Condition
    Cumulative >= 7 days' supply of immediate‑release (IR) opioid within past 90 days
    OR cumulative >= 30 days' supply of extended‑release (ER) opioid within past 90 days
    Opioid IR Short‑Course AllowanceLimit
    Applies to OPIOID IR COMBO PRODUCTS (Group 1358‑E)
    Coverage allowed for up to a 7‑day supply if the member does not have at least a cumulative 7‑day supply of any opioid (IR or ER) in the past 90 days
    Opioid ER Coverage RequirementRequired Prior Exposure
    OPIOID ER group (Group 2219‑M)
    Member must have either a cumulative >=7‑day IR opioid fill in the past 90 days OR a cumulative >=30‑day ER opioid supply in the past 90 days to obtain ER opioid coverage
    High‑Risk Opioid ProductsFormulary Controls
    Certain fentanyl transdermal patches (multiple strengths)
    These patches are subject to Step Therapy (ST), quantity limits (QL), and many higher strengths require prior authorization (PA) or are flagged 'High Strength Requires PA'
    ER Opioid Entries Requiring ST/PA**Notes
    Selected extended‑release opioid products (e.g., hydromorphone ER, morphine ER, hydrocodone ER)
    Many ER products are marked ST and may also require PA**; coverage contingent on meeting step‑therapy opioid exposure or obtaining PA when steps unmet
    Products Subject to Step TherapyFormulary Indication
    Selected opioid combination analgesics, buprenorphine films/patches, and select hydrocodone/oxycodone combinations
    Step Therapy (ST) is indicated alongside entries; specific step sequences are provided in the therapeutic‑class sections of the formulary rather than in the summary
    ZURZUVAE (zuranolone) SP FlagImplication
    ZURZUVAE entries are labeled SP (special program) and show PA and QL
    SP flag may indicate management via a specialty program or additional step/program requirements; explicit step sequence is not provided in this excerpt

    Quantity Limits and Measurement Periods

    Quantity-limit (QL) determination rule
    Basis for QL determinationsQLs are set to a determined number of doses not to exceed the FDA maximum approved dose
    RationaleLimits may reflect safety, overdose risk, abuse potential, or usual monthly dosing
    Override processPrescriber may request quantity exceeding QL via Prior Authorization with medical necessity documentation
    Generic amphetamine QL examples
    Generic amphetamine QL examples360 / 180 / 90 tablets (examples: 360 tabs every 75 days; 180 tabs every 75 days; 90 tabs every 75 days)
    Product-dependenceExact QL varies by formulation and strength as listed in formulary entries
    Age-based PAMany entries require PA for members age ≥19 in addition to QL
    Multiple amphetamine/dextroamphetamine QL examples
    Multiple product QL examplesExamples across amphetamine/dextroamphetamine products include 360, 270, 180, and 90 caps/tabs every 75 days (product-dependent)
    Solution QL exampleSome oral solutions limited (e.g., 3600 mL every 75 days for dextroamphetamine solution)
    PA requirementPA commonly required for age ≥19 alongside QL
    Atomoxetine quantity limit
    Atomoxetine QL360 capsules every 75 days
    PA and MOAtomoxetine entries show PA and MO where indicated
    Age notePA often required for members age ≥19 per formulary entries
    Various stimulant QL examples
    Stimulant QL examplesExamples include 540, 360, 270, 180, and 90 tablets/caps per 75 days depending on product and strength
    Solution volumesSome nebulizer or oral solution volumes listed (e.g., 5400 mL, 2700 mL per 75 days)
    PA and agePA typically required for members age ≥19 in addition to QL
    Methylphenidate ER/OROS and patch QLs
    Methylphenidate ER/OROS and patch QLQLs commonly 90 or 180 units every 75 days depending on product and strength
    PA for adultsPA required for members age ≥19 for many ER/OROS and patch products
    Formulation-specificExact counts vary by specific formulation as listed in formulary entries
    Apremilast (Otezla) quantity limits
    Apremilast (Otezla) QL55 tablets every 28 days (or 41 tabs for a 28‑day pack where specified)
    DesignationOtezla listed SP, PA, QL in formulary entries
    Preferred indicationsPreferred for Psoriasis and Psoriatic Arthritis per formulary notes
    Aspirin 81 mg quantity limit
    Aspirin 81 mg QL100 tablets (every 30 days)
    Pregnancy prevention note$0 copay for members capable of pregnancy age 12–59 at risk for preeclampsia
    OtherwiseOtherwise not covered except as specified
    Fentanyl patch quantity limits
    Fentanyl patch QL10 patches every 25 days
    High-strength PAHigher‑strength fentanyl patches require PA (High Strength Requires PA)
    Step therapy flagSome patch strengths are subject to ST in addition to QL
    Codeine sulfate 30 mg quantity limit
    Codeine sulfate 30 mg QL42 tablets every 25 days
    Initial limitSubject to initial 7‑day limit; if age 19 or younger, subject to initial 3‑day limit
    Coverage flagPA and QL apply as listed
    Hydrocodone bitartrate ER 10 mg quantity limit
    Hydrocodone bitartrate ER 12hr 10 mg QL60 caps every 25 days
    ST/PAProduct marked ST and PA** for certain strengths
    Initial supplySubject to initial 7‑day limit; 3‑day if age 19 or younger where specified
    Various opioid and combination QL examples
    Various opioid examples (QL)Examples include product‑specific QLs such as 300 caps every 25 days for TREZIX; 48 caps every 25 days for butalbital combos; 2700 mL every 25 days for hydrocodone solution
    Initial limitsMany entries subject to initial 7‑day limit (3‑day if age ≤19)
    PA/ST applicabilityHigh‑strength products often require PA; some products are ST/PA**
    TREZIX and related combination caps QL
    TREZIX QL300 caps every 25 days
    ST and PA**Entry indicates ST and PA** and subject to initial limits
    Age restrictionNot available under age 12 for specified products in this family
    Butalbital combination caps QL
    Butalbital‑acetaminophen‑caffeine with codeine caps QL48 caps every 25 days
    Age restrictionNot available under age 12 for these products
    QL enforcementSubject to QL and initial supply limits as listed
    Hydrocodone‑acetaminophen solution QL
    Hydrocodone‑acetaminophen solution QL2700 mL every 25 days (formulation‑specific)
    Initial supplySubject to initial 7‑day limit; 3‑day if age 19 or younger
    PA/QLCoverage subject to QL and PA flags as listed
    Hydrocodone‑acetaminophen tablet QLs
    Hydrocodone‑acetaminophen tablets QL240 tablets every 25 days (varies by strength: some entries 180 or 240)
    Initial supplySubject to initial 7‑day limit; 3‑day if age 19 or younger where indicated
    ST/PA flagsSome strengths marked ST or PA** as noted
    Oxycodone with acetaminophen QLs
    Oxycodone w/ acetaminophen QL180–360 tablets every 25 days depending on strength
    Initial supplySubject to initial 7‑day limit; 3‑day if age 19 or younger
    PA/STMany strengths marked ST and/or PA**
    BELBUCA film quantity limits
    BELBUCA films QL60 films every 25 days for most strengths
    ST/PA**Many BELBUCA strengths marked ST and PA**; highest strengths require PA
    High‑strength handlingBELBUCA 600 mcg and above flagged as High Strength Requires PA
    Buprenorphine transdermal patch QL
    Buprenorphine transdermal patches QL4 patches every month
    ST/PALower strengths may be ST/QL; higher strengths (15–20 mcg/hr) require PA
    Specialty/siteSome buprenorphine products have additional coverage flags (PA, ST, QL)
    Tramadol‑acetaminophen QL
    Tramadol‑acetaminophen 37.5–325 mg QL40 tablets every 25 days
    Initial limitSubject to initial 7‑day limit; initial 3‑day limit if age 19 or younger where noted
    ST/PA flagsMany combination products marked ST and/or PA**
    Pentazocine w/ naloxone QL
    Pentazocine w/ naloxone 50‑0.5 mg QL120 tablets every 25 days
    Initial supplySubject to initial 7‑day limit; 3‑day if age 19 or younger
    Coverage flagsPA and QL apply as listed
    Alprazolam quantity limits
    Alprazolam QL150 tablets every 25 days for most strengths; ER 3 mg = 90 tabs every 25 days
    ScopeApplies to multiple alprazolam formulations including ODT and ER forms
    OverrideRequests exceeding QL require documentation/override justification
    Chlordiazepoxide and related QLs
    Chlordiazepoxide caps QL360 caps every 25 days
    Diazepam concentrate & oral solution QL240 mL (conc) and 1200 mL (oral solution) every 25 days
    Benzodiazepine QLsMultiple benzodiazepines have specified QLs per 25‑day period
    Diazepam QLs
    Diazepam concentrate QL240 mL every 25 days (concentrate)
    Diazepam oral solution QL1200 mL every 25 days (oral solution)
    Tablet QL120 tablets every 25 days for specified tablet strengths
    Cromolyn sodium nebule QL
    Cromolyn sodium nebule QL720 mL every 75 days
    Measurement periodCommon QL measurement period is every 75 days for inhalation/nebulizer products
    MO flagOften listed with MO indicating managed limits
    Ipratropium HFA inhaler QL
    Ipratropium HFA inhaler QL6 inhalers every 75 days
    MOListed as MO (managed/maintenance) in formulary entries
    Measurement periodEvery 75 days
    Spiriva HandiHaler and Respimat QLs
    Spiriva HandiHaler caps QL90 caps every 75 days
    Spiriva Respimat QL3 inhalers every 75 days for Respimat
    Other inhaler volumesSome products have mL limits instead (e.g., 270 mL every 75 days)
    Spiriva Respimat and inhaler QLs
    Spiriva Respimat / other inhalers QL3 inhalers every 75 days (Respimat) or 270 mL every 75 days for some nebulized products
    Measurement periodEvery 75 days
    MO flagOften noted as MO alongside QL
    Cromolyn sodium solution QL
    Cromolyn sodium soln nebu 20 mg/2 mL QL720 mL every 75 days
    UnitmL per measurement period
    Managed flagListed with MO where applicable
    Ipratropium bromide HFA QL
    Ipratropium bromide HFA 17 mcg/act QL6 inhalers every 75 days
    Measurement periodEvery 75 days
    MOListed with MO in formulary entries
    Montelukast, mometasone, fluticasone QLs
    Montelukast QL/flagNoted as MO or unspecified QL where indicated (managed/maintenance limits)
    Mometasone (Asmanex) QL3 inhalers every 75 days
    Fluticasone furoate QL3 inhalers or 90 blisters every 75 days depending on formulation
    Pulmicort and albuterol QL examples
    Pulmicort (budesonide) QL9 inhalers (90 mcg) or 6 inhalers (180 mcg) every 75 days
    Albuterol examplesExamples include 6 inhalers or 180 mL or larger mL volumes per 75 days depending on formulation
    MO flagOften listed as MO alongside QL
    Breo Ellipta, Anoro, Wixela QLs
    Breo Ellipta / Anoro QL3 inhalers every 75 days or 180 blisters for some formulations
    Wixela Inhub QL180 inhalations every 75 days
    Formulation dependenceExact QL depends on device/formulation (inhalers vs blisters)
    Formoterol and levalbuterol nebulizer solution QLs
    Formoterol / levalbuterol nebulizer QLsExamples include 360 mL, 900 mL, or 270 mL every 75 days depending on concentration
    Measurement periodEvery 75 days
    MO flagOften listed as MO alongside QL
    Theophylline QL status
    Theophylline QL statusListed as MO (managed/standard limits) without numeric QL in this section
    ImplicationMO indicates managed coverage; numeric QLs may be defined elsewhere
    Provider actionSubmit PA/justification when requesting quantities beyond typical limits
    Anticoagulants QL / MO flags
    Anticoagulants/Thrombin inhibitors QL statusCoverage requirements and limits shown as MO or blank; numeric QLs not specified here
    ExamplesWarfarin, apixaban, rivaroxaban, dabigatran entries appear with MO flags
    Provider actionFollow PA/MO instructions when present on product line
    Clonazepam quantity limit
    Clonazepam QL300 tablets every 25 days (applies to multiple clonazepam formulations)
    ScopeIncludes ODT and tablet strengths listed in formulary entries
    OverrideRequests exceeding QL require documentation/override justification
    Brivaracetam (BRIVIACT) quantity limit
    Brivaracetam (BRIVIACT) QLQuantity limit shown as '2' in AND LIMITS column for certain presentations
    MO flagEntries also list MO alongside numeric limit where indicated
    ActionFollow product‑level PA/MO/QL procedures for requests exceeding limits
    ZURZUVAE (zuranolone) QLs
    ZURZUVAE cap QLQL: 2 caps every 1 day for some strengths; 1 cap every 1 day for 30 mg
    FlagsEntries show MO, PA, and QL (and SP) as applicable
    ApplicabilityProduct‑specific per formulary lines
    Ondansetron and granisetron QLs
    Ondansetron oral solution QL200 mL every 21 days
    Ondansetron tablet/disintegrating QL18 tablets every 21 days
    Granisetron tab QL12 tablets every 21 days
    Ondansetron / Sancuso / dronabinol QLs
    Ondansetron tablets QL18 tabs every 21 days (including ODT forms)
    Sancuso patch QL2 patches every 21 days
    Dronabinol QL60 capsules every 25 days
    Specialty pharmacy / mail order / retail site‑of‑care
    Specialty dispensingSpecialty drugs dispensed via CVS Specialty Pharmacy and mailed to member
    Retail submissionSpecialty prescriptions presented at CVS retail are forwarded to CVS Specialty for fulfillment
    Mail orderMail‑order medications available via CVS Caremark

    Dispensing Channels and Supply Options

    Note

    Specialty drugs dispensed via CVS Specialty

    Specialty drugs are dispensed through CVS Specialty Pharmacy and mailed; specialty prescriptions presented at CVS retail will be forwarded to CVS Specialty for fulfillment.

    • Providers should direct specialty drug prescriptions to CVS Specialty® Pharmacy enrollment at CVSspecialty.com.
    • Alternatively, prescriptions brought to CVS retail will be sent to CVS Specialty for processing.
    Billing Rule

    MO drugs eligible for 90‑day retail or mail‑order fills

    Maintenance drugs (MO) can be filled for a 90‑day supply at retail or via mail order through CVS Caremark; providers should advise members about mail order enrollment options.

    • MO designation permits up to a 90‑day supply through retail or CVS Caremark mail order.
    • Enroll at info.caremark.com/mailservice for mail order fulfillment.

    Background and Definitions

    The formulary organizes covered outpatient prescription drugs by therapeutic class and includes definitions and program guidance for Prior Authorization (PA), Step Therapy (ST), Quantity Limits (QL), Specialty (SP) designations, and other managed‑coverage flags (e.g., MO). It functions as the master drug list for employer‑sponsored Large Group HMO and POS plans using a 4‑tier formulary and provides instructions on coverage requirements, utilization management, and where to find plan‑specific cost‑sharing information.

    Formulary (definition)
    Formulary definitionThe complete list of drugs preferred for use and eligible for coverage under Sharp Health Plan (Prescription Drug List)
    IncludesInformation on tiers, coverage requirements, and limits as outlined in the document
    Used forDetermines outpatient prescription benefit coverage under the plan
    Prior Authorization (PA) definition and process
    Prior Authorization (PA)A coverage requirement where the Prescribing Provider must obtain approval before Sharp Health Plan will cover the drug; decisions rendered within 72 hours for non‑urgent requests or 24 hours for urgent/Exigent Circumstances
    Submission methodsPA requests via phone, fax, or electronic Prior Authorization Form with required supporting clinical information
    PA**PA** denotes PA based on specific clinical criteria if Step Therapy is not met
    Step Therapy definition and exceptions
    Step TherapyA required sequence of drugs a member must try before coverage of an alternative drug is allowed; exceptions may be granted when the criteria are met
    ExceptionsProviders may request a Step Therapy Exception with clinical justification; if plan does not respond in required timeframe the exception is deemed granted
    Continuity of careMembers transitioning from another insurer and already taking the medication are generally exempt from restarting Step Therapy
    Exigent Circumstances (definition)
    Exigent CircumstancesSituations when a member's condition may seriously jeopardize life, health, or ability to regain maximum function; triggers expedited (24‑hour) review
    Effect on timingPA and Step Therapy exception requests based on exigent circumstances decided within 24 hours
    ContinuationCoverage provided for the duration of the exigency when approved
    Specialty Drug (definition)
    Specialty Drug (SP)Drugs that must be distributed through a specialty pharmacy, require special training or clinical monitoring for self‑administration, or designated specialty by P&T Committee
    Dispensing channelSpecialty drugs dispensed through CVS Specialty per formulary site‑of‑care guidance
    ManagementOften subject to SP, PA, and QL controls
    Cumulative opioid supply (definition)
    Cumulative opioid supply — definitionTotal days' supply of opioid fills within a specified lookback period (used to calculate step therapy thresholds)
    ExamplesCumulative 7 days (IR) or 30 days (ER) within past 90 days used to determine eligibility for ER opioid coverage
    DocumentationPharmacy fill history required to demonstrate cumulative supply for PA/step therapy
    MO (Medication Override / managed limits)
    MO (Medication Override)Formulary shorthand indicating managed/standard limits or member‑only handling as listed in coverage requirements and limits
    ImplicationMO entries may still require documentation or PA per product notes
    Provider actionFollow product‑level MO instructions when present on formulary line
    QL (Quantity Limit) definition
    QL (Quantity Limit)Maximum number of units (tabs/caps/patches/inhalers/mL) allowed in a specified measurement period (commonly every 75 days); requests above QL require PA with medical necessity
    Measurement period examplesCommon periods: every 25 days, every 28 days, every 75 days, or every 21 days depending on product
    Override processProvider may submit PA to request quantity exceeding QL with justification
    SP (Specialty) definition
    SP (Specialty) flagIndicates specialty drug designation requiring management through specialty pharmacy channels
    ExamplesUsed for select antirheumatic agents and apremilast (Otezla) entries
    ImplicationSP items often require PA and have QLs
    Initial opioid limit (definition)
    Initial opioid limit (definition)Programmatic limit on initial opioid prescriptions: 7‑day limit for adults; 3‑day limit for patients age 19 or younger
    ApplicationApplied to many opioid and combination product entries in the formulary
    EnforcementMay be enforced at point of dispensing and via PA/ST rules